According to a study published in Radiology, a journal of the Radiological Society of North America, researchers are employing a technique known as radiomics to
To evaluate the effects of dentin pretreatment with chitosan-loaded oleuropein nanoparticles (CONPs) on the durability of resin-dentin bonding interfaces.
Professor Wei Han discusses the importance of, and developments in, the ‘Pathogenesis and Clinical Treatment Strategies of Oral Cancer’. Submit your research on this topic to our upcoming BioMed Research International special issue below.
Share this article
Share this article
SAN FRANCISCO and SUZHOU, China, Feb. 8, 2021 /PRNewswire/ Innovent Biologics, Inc. ( Innovent ) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that the first patient has been successfully enrolled and dosed in the randomized, open-label, phase III, multicenter clinical study (NCT04720716) evaluating its IBI310 (anti CTLA-4 monoclonal antibody) in combination with TYVYT® (sintilimab injection) for the first-line treatment of patient with advanced hepatocellular carcinoma (HCC).
In recent years, immune checkpoint inhibitors have brought new hope to HCC patient population with acceptable safety and encouraging efficacy. NCT04720716 is a randomized, open-label, controlled, multicenter phase III study evaluating the efficacy and safety of IBI310 in combination with TYVYT® (sin